Tonghua Dongbao Pharmaceutical Co.,ltd
Clinical trials sponsored by Tonghua Dongbao Pharmaceutical Co.,ltd, explained in plain language.
-
New insulin candidate tested in 1,040 chinese diabetes patients
Disease control CompletedThis study tested a new insulin called THDB0206 against a standard insulin (lispro) in 1,040 Chinese adults with type 2 diabetes. Both groups also used a long-acting insulin (glargine). The goal was to see if the new insulin works as well or better at controlling blood sugar over…
Phase: PHASE3 • Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New insulin rival tested in 550 chinese patients with type 1 diabetes
Disease control CompletedThis study tested a new insulin called THDB0206 against a standard insulin (lispro) in 550 Chinese adults with type 1 diabetes. Both groups also used a long-acting insulin (glargine). The main goal was to see how well the new insulin controls blood sugar over 26 weeks. Participan…
Phase: PHASE3 • Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Where you inject insulin may matter: new study tests injection sites
Knowledge-focused CompletedThis study looked at how a single dose of a new insulin, THDB0206, is absorbed and works when injected into different body sites. It involved 27 healthy Chinese adults. The goal was to understand if injection location affects how the insulin behaves in the body.
Phase: PHASE1 • Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd • Aim: Knowledge-focused
Last updated May 11, 2026 20:50 UTC